07.24.12
26. Fresenius Medical Care
$3.3 Billion ($12.8B total)
KEY EXECUTIVES:
Ulf M. (Mark) Schneider, Chairman of the Board
Ben J. Lipps, CEO Fresenius Medical Care
Rainer Baule, CEO Fresenius Kabi
Stephan Sturm, Chief Financial Officer
NO. OF EMPLOYEES: 79,159 (total)
GLOBAL HEADQUARTERS: Bad Homburg, Germany
With chronic kidney failure a condition that affects more than 2 million people worldwide, Fresenius Medical Care AG & Co. is preparing itself for continued market growth. Through its network of 3,200 dialysis clinics worldwide, the company provides dialysis treatment to 253,000 patients around the globe—which comprises the bulk of the company’s revenue stream. To make it onto this list, however, Fresenius also is one of the world’s largest manufacturers of dialysis devices and products such as hemodialysis machines, dialyzers and related disposable products.
Overall, the company continues to post solid, steady results year after year.
For fiscal 2011 (ended Dec. 31) Fresenius Medical Care reported sales increase of 6 percent to $12.8 billion. According to the company, organic sales growth was 2 percent; acquisitions contributed 3 percent; and currency translation had an effect of 1 percent. Sales of dialysis services increased by 5 percent to $9.5 billion, up from approximately $9.1 billion. On the device side, dialysis product sales grew by 10 percent to $3.3 billion, up from nearly $3 billion last year.
In North America sales were $8.2 billion, nearly unchanged from $8.1 billion from fiscal 2010. Dialysis services sales were $7.3 billion, unchanged from 2010. Dialysis product sales decreased 2 percent to $813 million. International sales more than made up for stagnate U.S. sales, growing 18 percent to $4.6 billion, compared to $3.9 billion during the previous fiscal year. Sales in dialysis services increased 23 percent to $2.2 billion. Dialysis product sales increased 14 percent to $2.5 billion, mainly driven by higher sales of peritoneal dialysis products, dialyzers, dialysis machines and acute care products, company officials reported. Overall company earnings before interest and taxes (EBIT) increased 8 percent to $2.1 billion, up from $1.9 billion. Net income increased 9 percent to $1.1 billion, up from $979 million in 2010.
On the patient care side, Fresenius made a series of acquisitions and mergers in North America and Europe, including: American Access Care; International Dialysis Centers; the international dialysis service business of Euromedic; and Liberty Dialysis Holdings Inc., the holding company for Liberty Dialysis and Renal Advantage.
On the device front, Fresenius Medical Care AG & Co. purchased the assets of Hema Metrics LLC related to the company’s Crit-Line system, which enables non-invasive optical measurement of blood parameters such as percent blood volume change, absolute hematocrit level and continuous oxygen saturation. Crit-Line provides clinicians with a new tool to improve fluid management with less clinical complications, such as hypotension, according to Fresenius. Improved fluid management may lead to fewer hospitalizations for renal patients. Accurate hematocrit measurement, real time, provides the clinician immediate feedback, supporting anemia management. The Crit-Line system and its associated products have been 510(k) cleared by the U.S. Food and Drug Administration, and carry the CE Mark in Europe. Fresenius plans to establish this technology as the standard of care for fluid and anemia management in the North American market.
As part of an increasingly global strategy, Fresenius is expanding its production capacity in Southeast Asia. Fresenius’ Kabi division, a maker of infusion therapy and clinical nutrition, opened a new production facility in the coastal city Quy Nhon in central Vietnam. Nearly 380 employees will work at the production facility. With the new plant, Fresenius Kabi will almost double its manufacturing capacity for infusion solutions and liquid medications. Most of these products are intended for the Vietnamese market.
Ulf Mark Schneider, CEO of Fresenius, said: “Health care systems in Vietnam and other countries in Southeast Asia are developing at a rapid pace, so there is a constantly increasing demand for Fresenius Kabi products in these countries. Our new plant in Quy Nhon will help us meet this demand and allow us to make a significant contribution to high-quality, yet affordable health care in the region.”
The new plant replaces the existing Fresenius Kabi production facility in Quy Nhon. The new production facility covers 15,000 square meters. The manufacture of infusion solutions already is certified in line with GMP (good manufacturing practice) guidelines set by the World Health Organization. The plant is run by Fresenius Kabi Bidiphar JSC, a joint venture between Fresenius Kabi and Bidiphar, a state-owned health care company based in Quy Nhon. Fresenius Kabi Bidiphar was founded in 2008, and Fresenius Kabi holds the majority of its shares and provides the management team.
For 2012, Fresenius executives expect to grow sales to $14 billion. Net income is expected to grow to $1.3 billion.
$3.3 Billion ($12.8B total)
KEY EXECUTIVES:
Ulf M. (Mark) Schneider, Chairman of the Board
Ben J. Lipps, CEO Fresenius Medical Care
Rainer Baule, CEO Fresenius Kabi
Stephan Sturm, Chief Financial Officer
NO. OF EMPLOYEES: 79,159 (total)
GLOBAL HEADQUARTERS: Bad Homburg, Germany
With chronic kidney failure a condition that affects more than 2 million people worldwide, Fresenius Medical Care AG & Co. is preparing itself for continued market growth. Through its network of 3,200 dialysis clinics worldwide, the company provides dialysis treatment to 253,000 patients around the globe—which comprises the bulk of the company’s revenue stream. To make it onto this list, however, Fresenius also is one of the world’s largest manufacturers of dialysis devices and products such as hemodialysis machines, dialyzers and related disposable products.
Overall, the company continues to post solid, steady results year after year.
For fiscal 2011 (ended Dec. 31) Fresenius Medical Care reported sales increase of 6 percent to $12.8 billion. According to the company, organic sales growth was 2 percent; acquisitions contributed 3 percent; and currency translation had an effect of 1 percent. Sales of dialysis services increased by 5 percent to $9.5 billion, up from approximately $9.1 billion. On the device side, dialysis product sales grew by 10 percent to $3.3 billion, up from nearly $3 billion last year.
In North America sales were $8.2 billion, nearly unchanged from $8.1 billion from fiscal 2010. Dialysis services sales were $7.3 billion, unchanged from 2010. Dialysis product sales decreased 2 percent to $813 million. International sales more than made up for stagnate U.S. sales, growing 18 percent to $4.6 billion, compared to $3.9 billion during the previous fiscal year. Sales in dialysis services increased 23 percent to $2.2 billion. Dialysis product sales increased 14 percent to $2.5 billion, mainly driven by higher sales of peritoneal dialysis products, dialyzers, dialysis machines and acute care products, company officials reported. Overall company earnings before interest and taxes (EBIT) increased 8 percent to $2.1 billion, up from $1.9 billion. Net income increased 9 percent to $1.1 billion, up from $979 million in 2010.
On the patient care side, Fresenius made a series of acquisitions and mergers in North America and Europe, including: American Access Care; International Dialysis Centers; the international dialysis service business of Euromedic; and Liberty Dialysis Holdings Inc., the holding company for Liberty Dialysis and Renal Advantage.
On the device front, Fresenius Medical Care AG & Co. purchased the assets of Hema Metrics LLC related to the company’s Crit-Line system, which enables non-invasive optical measurement of blood parameters such as percent blood volume change, absolute hematocrit level and continuous oxygen saturation. Crit-Line provides clinicians with a new tool to improve fluid management with less clinical complications, such as hypotension, according to Fresenius. Improved fluid management may lead to fewer hospitalizations for renal patients. Accurate hematocrit measurement, real time, provides the clinician immediate feedback, supporting anemia management. The Crit-Line system and its associated products have been 510(k) cleared by the U.S. Food and Drug Administration, and carry the CE Mark in Europe. Fresenius plans to establish this technology as the standard of care for fluid and anemia management in the North American market.
As part of an increasingly global strategy, Fresenius is expanding its production capacity in Southeast Asia. Fresenius’ Kabi division, a maker of infusion therapy and clinical nutrition, opened a new production facility in the coastal city Quy Nhon in central Vietnam. Nearly 380 employees will work at the production facility. With the new plant, Fresenius Kabi will almost double its manufacturing capacity for infusion solutions and liquid medications. Most of these products are intended for the Vietnamese market.
Ulf Mark Schneider, CEO of Fresenius, said: “Health care systems in Vietnam and other countries in Southeast Asia are developing at a rapid pace, so there is a constantly increasing demand for Fresenius Kabi products in these countries. Our new plant in Quy Nhon will help us meet this demand and allow us to make a significant contribution to high-quality, yet affordable health care in the region.”
The new plant replaces the existing Fresenius Kabi production facility in Quy Nhon. The new production facility covers 15,000 square meters. The manufacture of infusion solutions already is certified in line with GMP (good manufacturing practice) guidelines set by the World Health Organization. The plant is run by Fresenius Kabi Bidiphar JSC, a joint venture between Fresenius Kabi and Bidiphar, a state-owned health care company based in Quy Nhon. Fresenius Kabi Bidiphar was founded in 2008, and Fresenius Kabi holds the majority of its shares and provides the management team.
For 2012, Fresenius executives expect to grow sales to $14 billion. Net income is expected to grow to $1.3 billion.
< Previous - CareFusion | Bayer - Next > |